Yesterday, the SVP & GC of Quest Diagnostics (DGX), Michael Prevoznik, sold shares of DGX for $4.24M.
Following Michael Prevoznik’s last DGX Sell transaction on December 04, 2019, the stock climbed by 13.7%.
See today’s analyst top recommended stocks >>
The company has a one-year high of $131.81 and a one-year low of $73.02. Currently, Quest Diagnostics has an average volume of 510.11K. DGX’s market cap is $15.67 billion and the company has a P/E ratio of 21.30.
Based on 9 analyst ratings, the analyst consensus is Strong Buy with an average price target of $145.13, reflecting a -19.9% downside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Read More on DGX:
